Pediatric Episodic Migraine with Aura: A Unique Entity?

Overview

Journal Children (Basel)

Specialty Health Services

Date 2021 Apr 3

PMID 33802676

Citations 1

Authors

Hannah F J Shapiro

Alyssa Lebel

Affiliations

Soon will be listed here.

Abstract

Migraine headache is a common cause of pain and disability in children and adolescents and is a major contributor to frequently missed school days and limitations in activities. Of children and adolescents with migraine headache, approximately one-third have migraine with aura (MA). MA is often considered to be similar to migraine without aura (MO), and thus, many studies do not stratify patients based on the presence of aura. Because of this, treatment recommendations are often analogous between MA and MO, with a few notable exceptions. The purpose of this review is to highlight the current evidence demonstrating the unique pathophysiology, clinical characteristics, differential diagnosis, co-morbidities, and treatment recommendations and responses for pediatric MA.

Citing Articles

A Narrative Review of Visual Hallucinations in Migraine and Epilepsy: Similarities and Differences in Children and Adolescents.

DAgnano D, Lo Cascio S, Correnti E, Raieli V, Sciruicchio V Brain Sci. 2023; 13(4).

PMID: 37190608 PMC: 10136509. DOI: 10.3390/brainsci13040643.

References

Balestri M, Papetti L, Maiorani D, Capuano A, Tarantino S, Battan B . Features of aura in paediatric migraine diagnosed using the ICHD 3 beta criteria. Cephalalgia. 2017; 38(11):1742-1747. DOI: 10.1177/0333102417748571. View

Kroon Van Diest A, Ernst M, Vaughn L, Slater S, Powers S . CBT for Pediatric Migraine: A Qualitative Study of Patient and Parent Experience. Headache. 2018; 58(5):661-675. PMC: 5992027. DOI: 10.1111/head.13285. View

Lipton R, Dodick D, Ailani J, Lu K, Finnegan M, Szegedi A . Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019; 322(19):1887-1898. PMC: 6865323. DOI: 10.1001/jama.2019.16711. View

Moskowitz M . Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 1993; 43(6 Suppl 3):S16-20. View

Turner S, Szperka C, Hershey A, Law E, Palermo T, Groenewald C . Association of Headache With School Functioning Among Children and Adolescents in the United States. JAMA Pediatr. 2021; 175(5):522-524. PMC: 7851753. DOI: 10.1001/jamapediatrics.2020.5680. View

OBrien H, Kabbouche M, Hershey A . Treating pediatric migraine: an expert opinion. Expert Opin Pharmacother. 2012; 13(7):959-66. DOI: 10.1517/14656566.2012.677434. View

Friedman D, Evans R . Are Blurred Vision and Short-Duration Visual Phenomena Migraine Aura Symptoms?. Headache. 2017; 57(4):643-647. DOI: 10.1111/head.13042. View

Lewis D, Winner P . The pharmacological treatment options for pediatric migraine: an evidence-based appraisal. NeuroRx. 2006; 3(2):181-91. PMC: 3593442. DOI: 10.1016/j.nurx.2006.01.002. View

Viana M, Linde M, Sances G, Ghiotto N, Guaschino E, Allena M . Migraine aura symptoms: Duration, succession and temporal relationship to headache. Cephalalgia. 2015; 36(5):413-21. DOI: 10.1177/0333102415593089. View

10.

Reuter U, Del Rio M, Diener H, Allais G, Davies B, Gendolla A . Migraines with and without aura and their response to preventive therapy with topiramate. Cephalalgia. 2009; 30(5):543-51. DOI: 10.1111/j.1468-2982.2009.01999.x. View

11.

Powers S, Hershey A, Coffey C, Chamberlin L, Ecklund D, Sullivan S . The Childhood and Adolescent Migraine Prevention (CHAMP) Study: A Report on Baseline Characteristics of Participants. Headache. 2016; 56(5):859-870. PMC: 5050048. DOI: 10.1111/head.12810. View

12.

Goadsby P, Edvinsson L . The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993; 33(1):48-56. DOI: 10.1002/ana.410330109. View

13.

Viana M, Afridi S . Migraine with prolonged aura: phenotype and treatment. Naunyn Schmiedebergs Arch Pharmacol. 2017; 391(1):1-7. DOI: 10.1007/s00210-017-1438-4. View

14.

Hansen J, Lipton R, Dodick D, Silberstein S, Saper J, Aurora S . Migraine headache is present in the aura phase: a prospective study. Neurology. 2012; 79(20):2044-9. PMC: 3511920. DOI: 10.1212/WNL.0b013e3182749eed. View

15.

Clarke B, Upton A, Kamath M, Al-Harbi T, Castellanos C . Transcranial magnetic stimulation for migraine: clinical effects. J Headache Pain. 2006; 7(5):341-6. PMC: 3468174. DOI: 10.1007/s10194-006-0329-8. View

16.

Varkey E, Cider A, Carlsson J, Linde M . Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia. 2011; 31(14):1428-38. PMC: 3236524. DOI: 10.1177/0333102411419681. View

17.

Powers S, Coffey C, Chamberlin L, Ecklund D, Klingner E, Yankey J . Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. N Engl J Med. 2016; 376(2):115-124. PMC: 5226887. DOI: 10.1056/NEJMoa1610384. View

18.

Qubty W, Patniyot I . Migraine Pathophysiology. Pediatr Neurol. 2020; 107:1-6. DOI: 10.1016/j.pediatrneurol.2019.12.014. View

19.

Grogan P, Alvarez M, Jones L . Headache direction and aura predict migraine responsiveness to rimabotulinumtoxin B. Headache. 2012; 53(1):126-136. DOI: 10.1111/j.1526-4610.2012.02288.x. View

20.

Winner P, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin M . A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine. Headache. 2020; 60(3):564-575. PMC: 7065250. DOI: 10.1111/head.13754. View